Does REPOTRECTINIB Cause Malignant neoplasm progression? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with REPOTRECTINIB (Augtyro). This represents 2.7% of all adverse event reports for REPOTRECTINIB.
5
Reports of Malignant neoplasm progression with REPOTRECTINIB
2.7%
of all REPOTRECTINIB reports
1
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From REPOTRECTINIB?
Of the 5 reports, 1 (20.0%) resulted in death, 2 (40.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REPOTRECTINIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does REPOTRECTINIB Cause?
Dizziness (32)
Death (21)
Nausea (12)
Adverse event (11)
Neuropathy peripheral (11)
Off label use (10)
Paraesthesia (10)
Balance disorder (9)
Pain (9)
Hospitalisation (8)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which REPOTRECTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
REPOTRECTINIB vs REQUIP
REPOTRECTINIB vs RESLIZUMAB
REPOTRECTINIB vs RESMETIROM
REPOTRECTINIB vs RESTASIS
REPOTRECTINIB vs RETINOL